Entering text into the input field will update the search result below

Provectus Biopharmaceuticals Is An Opportunity With Great Risk And Great Potential Reward

M Plaut profile picture
M Plaut


  • Provectus (PVCT) has a oncological immunotherapeutic drug in a Phase 3 trial.
  • Provectus also has a very promising psoriasis drug with results reported by Professor James G Kreuger of Rockefeller University.
  • New Management took over a year ago and has made encouraging changes.
  • None of this is priced into the current market price.

Provectus Biopharmaceuticals, Inc. is an Opportunity with Great Risk and Great Potential Reward

The last time I wrote about Provectus Biopharmaceuticals was over three years ago (Exciting Product Development Developments For Provectus' Lead Drug PV-10 ) so it seems time for an update.

First the good news. Provectus has two major drugs at relatively advanced stages of development: PV-10, a cancer drug, and PH-10, a dermatolgic drug. Both are solutions of Rose Bengal, a dye that has been in therapeutic use in humans for almost a century. Provectus has patent protection for special methods of manufacturing clinically pure Rose Bengal, as well as for its use in therapeutic purposes. You can read about its Intellectual Property here. (Patents).

Four trials are currently being run on PV-10. Two are on its use in treating melanoma. One is a Phase 3 trial: PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma. This is an international multicenter, open-label, randomized controlled trial (RCT) of single-agent intralesional PV-10 versus systemic chemotherapy or intralesional oncolytic viral therapy to assess treatment of locally advanced cutaneous melanoma. Further information here: (ClinicalTrials.gov )

It should be noted that reaching this stage is already a significant achievement. According to Fdareview.org only 9% of drugs make it to Phase 3. Cancer drugs are particularly difficult. However the published results of the Phase 2 study, available here, show that it was quit effective.

Also, PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma. This is an international multicenter, open-label, sequential phase study of intralesional (IL) PV-10 in combination with immune checkpoint inhibition. It is being studied together with Keytruda (pembrolizumab) which is owned by Merck (MRK). Similar drugs include Opdivo (nivolumab) that is owned by Bristol Myers-Squibb (BMY). Further information

This article was written by

M Plaut profile picture
M Plaut is a private investor and writer. I have been a full time investor since 2002, and I specialize in energy and financial companies. I have a strong bias for dividend paying stocks but am open to good opportunities wherever they present themselves. I have never worked for anyone else as an investment professional, but so far my personal performance in managing my own money has been ok.

Analyst’s Disclosure: I am/we are long PVCT. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.